Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

The Indian Ministry of Health & Family Welfare has identified 219 districts across the country as priority for intensified interventions for HIV/AIDS, as part of its strategy to control the epidemic by 2027.

The country aims to achieve HIV control by December 1, 2027. As part of its Mission AIDS Suraksha, the Ministry convened the regional workshops titled ‘Suraksha Sankalp Karyashala' in Delhi today.

The workshop laid a special focus on the states of Haryana and Delhi, to chart a targeted approach for program implementation and close monitoring of high-burden districts -- 11 in Haryana and 7 in Delhi.

In Delhi, the identified districts include North, New Delhi, Shahdara, Central, South East, South, and North West. In Haryana, the prioritized districts comprise Panipat, Rohtak, Sirsa, Jhajjar, Gurugram, Faridabad, Bhiwani, Hisar, Sonipat, Kaithal, and Fatehabad.

District program teams from these priority areas presented their progress, shared operational challenges, and collaboratively developed targeted, outcome-oriented action plans to further strengthen the HIV response at the grassroots level.

HIV Status In Delhi And Haryana

As per data from the Ministry, an estimated 59,079 people live with HIV in Delhi, with an adult HIV prevalence of 0.33 percent.

On the other hand, Haryana has an adult HIV prevalence of 0.24 percent, with an estimated 59,642 people living with HIV.

"Delhi continues to face critical gaps, with only around 70 percent of identified individuals currently linked to or receiving treatment, highlighting the urgent need to accelerate treatment coverage and retention,” said Dr. Rakesh Gupta, Additional Secretary & Director General, NACO.

"In contrast, Haryana has achieved a cascade of approximately 81:83:95, reflecting encouraging progress, while also signaling the need for intensified efforts to improve diagnosis and treatment linkage,” he added.

Focus Areas

HIV/AIDS A Public Health Challenge

By 2025, HIV targets were to ensure 95 percent people know their HIV status, 95 percent of them are on lifesaving antiretroviral therapy, and 95 percent of those on treatment are virally suppressed.

As per the National AIDS Control Organization’s report (Sankalak 2024), 81 percent of 25.44 lakh people living with HIV knew their status, 88 percent of them were receiving lifesaving antiretroviral therapy, and 97 percent of those on the treatment were virally suppressed till March 2024.

"HIV/AIDS continues to pose a significant public health challenge, necessitating sustained vigilance, innovation, and coordinated action across all tiers of governance,” said Dr. Gupta, in his keynote address.

Also read: Years After PrEP Rollout, The HIV Prevention Drug Still Remains A Privilege In India

Eliminating Vertical Transmission Of HIV

Dr. Gupta also emphazised the critical importance of eliminating mother-to-child transmission of HIV, which can occur during pregnancy, childbirth, and breastfeeding.

"Such transmission is entirely preventable through timely testing, counselling, and treatment, and called for strengthened antenatal screening and universal access to prevention services to ensure that no child is born with HIV," he added.

Also read: Reducing Mother-To-Child HIV Transmission To Zero Key To End AIDS In India: Experts

Stressing the need for a whole-of-system approach, Dr. Gupta called upon stakeholders across national, state, and district levels to work in close synergy, particularly at the field level, to bridge existing gaps in awareness, testing, treatment, and adherence.

The Suraksha Sankalp Karyashala serves as a vital platform for collaborative planning between national, State, and district stakeholders, reinforcing India’s coordinated, evidence-based, and data-driven approach to HIV prevention and testing services.

It aims to improve linkage and retention on treatment, enhance viral load suppression among people living with HIV, and expand targeted outreach among vulnerable and key populations.

Harish Rana, the 32-year-old resident from Ghaziabad who had been in vegetative condition for the last 13 years has now been removed from ventilators and other life support systems. He has been shifted to a normal bed. As per news reports, his water tube too was removed and a cap was placed on his feeding tube.

As per the hospital sources, Harish Rana's condition is now stable. Following the Supreme Court's order, the medical board will monitor his condition. While his feeding tube has been removed, doctors are still administering brain-soothing medicines.

Harish Rana's parents are also staying with him in AIIMS Delhi. His parents and brothers have been receiving daily counselling.

AIIMS Delhi Is Prepared For India's First Passive Euthanasia

Harish Rana's case marks India's first passive euthanasia. To conduct the passive euthanasia, AIIMS Delhi has set up a specialized team headed by professor and head of the department of anesthesia and palliative medicine, Dr Seema Mishra, has been constituted to implement the process. The team comprises doctors from departments of neurosurgery, onco-anesthesia, and palliative medicine, and psychiatry.

Read: AIIMS Delhi Sets Up Team To Process India's First Ever Passive Euthanasia For Harish Rana

“The process generally involves withholding or withdrawing the nutritional support gradually while ensuring adequate pain relief. The patient is given palliative sedation so that he or she is not in distress. Life support measures such as artificial nutrition, oxygen and medications are slowly withdrawn. The aim is not to prolong nor hasten death,” Dr Sushma Bhatnagar, former head of the department of onco-anaesthesia, pain and palliative care, AIIMS-Delhi.

What Happened To Harish Rana?

It was in 2013 when he suffered severe head injuries after he fell from the fourth floor from his PG accommodation while he was studying at Panjab University. He had been bedridden ever since, and survived on feeding tube. His father filed a petition seeking passive euthanasia under the guidelines Supreme Court had laid down in 2018 under Common Cause judgment. This is the second time the parents have approached the apex court.

In 2024, the court also suggested that Rana could receive home-based care with support from the Uttar Pradesh government. The home-based care includes periodic visits by doctors and physiotherapists. The court suggested that in case home care was not feasible, he could be moved to Noida's district hospital. However, his parents have noted that his condition continued to worsen. Family advocate Rashmi Nandakumar also informed the bench that "nothing seems to be working out".

"He is falling ill quite often and is repeatedly admitted to hospital," she said. The advocate further added that the family only sought passive euthanasia, which is withdrawal of treatment, and not any active intervention.

Justice Pardiwala also read medical reports and observed, "Just look at the condition of the boy. It's pathetic."

Recent court ruling on this case involves a bench comprising Justice JB Pardiwala and Justice KV Viswanathan that allowed the withdrawal of life support for Harish Rana, a resident of Ghaziabad, who has been in a coma and kept alive on tubes for breathing and nutrition after sustaining severe head injuries following a fall from a building in 2013 in Chandigarh.

Meningitis outbreak in Kent University that infected a dozen of people have now further infected more people. The total number as of now is 27, as experts say that incubation period of the bacteria may lead to an increase in number of those who are sick. However, health officials, as per The Guardian report, believe that they have contained the fatal outbreak, with "no cases emerging that are not linked to the original cluster of 20".

Read: UK Meningitis Outbreak: 9-month-old Baby Battles For Life In Intensive Care

The bug that causes the infection has been identified as the known strain of meningitis B and MenB vaccines will be offered to 5,000 students living in the University of Kent halls of residence in Cantebury. While several reports claim that parents are rushing to pharmacies to get their children vaccinated, due to which there is a shortage of the MenB vaccines, health secretary, Wes Streeting has denied any such claims. "There is actually plenty of stock of vaccine supply in the country," he said.

Read: Meningitis Outbreak From Kent University Is Now A National Incident, Parents Fighting For Jabs Amid Low Stock

As per the UK Health Security Agency (UKHSA) official, people infected in Kent were the ones who visited a nightclub on 5,6 or 7 March. The officials, including NHS members and county council public health staff who have been tackling the outbreak believe that it has not been passed on to anyone outside the area. "All cases to date are linked to the current outbreak in Kent," said a UKHSA spokesperson, as reported by The Guardian.

Another official involved in the multi-agency response said, "We may have contained it. There are no cases popping up elsewhere that we know of – no cases that we know of outside the cluster – or not yet anyway. We are rolling out a vaccine and antibiotics and tracing contacts. So there’s nothing we’re not doing.”

Quickest-growing Meningitis Outbreak Ever

UKHSA chief executive Susan Hopkins said the outbreak "looks like a super-spreader" event with "ongoing spread" through universities' halls of residence. She added: "There will have been some parties particularly around this, so there will have been lots of social mixing. I can't yet say where the initial infection came from, how it's got into this cohort, and why it's created such an explosive amount of infections."

She further said that in her 35 years working in medicine, healthcare, and hospitals, "This is the most cases I've ever seen in a single weekend with this type of infection". She added: "It is the explosive nature that is unprecedented here - the number of cases in such a short space of time." She also remarked that this was the "quickest-growing outbreak" she has ever seen in her career.

What Is Meningitis?

Meningitis is a serious medical condition that affects the protective membranes covering the brain and spinal cord, the meninges. While fever is not always present, it is usually considered as one of the classic symptoms of meningitis. It is important to know the varied symptoms, causes, and treatments of meningitis for early diagnosis and proper management of the disease.

Meningitis is an infectious illness that brings about inflammation in the meninges. The most common cause of such inflammation is bacterial or viral infections, though other causes are also possible including fungal, parasitic, or non-infectious causes (autoimmune disease, head injury, or brain surgery). Meningitis may be caused by bacterial meningitis, which the Centers for Disease Control and Prevention (CDC) indicates can be so severe and bring about conditions like hearing loss, vision problems, and death if not received on time.